This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
WKD Holding Oy
Drug Names(s): EG006
Description: Vitor is a formulation of imidapril (Tanatril), which was originally developed as a treatment for highblood pressure and is currently marketed in Japan and certain countries in Europe. Vitor reduces the production of Angiotensin (Ang) II at the tissue level. Ark has found that patients with muscle wasting exhibit abnormally high levels of Ang II, and that infusing Ang II causes muscle wasting in vivo. Its effect on muscle may be mediated by cytokines.
Ark has access to the Marketing Authorisation Application (MAA) of Tanabe, containing the safety, toxicology and efficacy studies which were required to approve the drug for its existing use in the treatment of high blood pressure.
In March 2013, WKD Holding acquired Ark Therapeutics, the drug development division of Ark Therapeutics Group.
Additional information available to subscribers only: